Recent Updates
Recently added Catalysts
KRYS Positive Sentiment

Krystal Biotech to Present at Upcoming Investor Conferences

Key Takeaway: Krystal Biotech will present at several upcoming investor conferences, including the Jefferies Global Healthcare Conference and the Evercore Healthcare Conference. Management will engage in fireside chats and host investor meetings. Presentations will be webcast live and archived for 30 days on the company's website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Management will participate in multiple investor conferences.
  • Live webcasts will be available for presentations.
  • Company focuses on high unmet medical needs with genetic medicines.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+54%
120-day peak, hindsight
Typical move
1.8%
average across 10 past catalysts
Lead asset
KB707
Phase 2 · Lung Cancer, Non-small Cell

Full Press Release Details

PITTSBURGH, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that management will take part in fireside chats and host investor meetings at the following conferences:

Jefferies Global Healthcare Conference in London

• November 17, 2026 in London, England
• Fireside chat scheduled for 8:00 am GMT

9th Annual Evercore Healthcare Conference

• December 1, 2026 in Coral Gables, Florida
• Fireside chat scheduled for 2:10 pm ET

Citi’s 2026 Global Healthcare Conference

• December 2, 2026 in Miami, Florida
• Fireside chat scheduled for 10:20 am ET
Each presentation will be webcast live and may be accessed through a link on the Investors section of the Company’s website. Archived versions of the webcasts will also be available on the Investors section of the Company’s website for at least 30 days.
About Krystal Biotech, Inc. Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. Visit www.krystalbio.com to learn more or follow us on LinkedIn and X.

CONTACT Investors and Media: Stéphane Paquette, PhD Krystal Biotech spaquette@krystalbio.com

Frequently Asked Questions

When will Krystal Biotech present at investor conferences?

Krystal Biotech will present on November 17, December 1, and December 2, 2026.

Where will the upcoming conferences take place?

The conferences will be held in London, Coral Gables, and Miami.

Will the presentations be available online?

Yes, the presentations will be webcast live and archived for 30 days.

What is Krystal Biotech's focus?

The company focuses on genetic medicines for diseases with high unmet needs.

Last updated: Nov 10, 2026